Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medmira ( (TSE:MIR) ) just unveiled an update.
MedMira reported second-quarter fiscal 2026 results marked by weaker revenue and a wider net loss, alongside a strategic expansion of its distribution network. The company signed a major agreement with McKesson in the U.S. and Canada, broadening access to private, state and federal customers for its FDA and Health Canada approved rapid tests and boosting brand visibility.
Operationally, MedMira advanced its pipeline with strong clinical data for the Multiplo Complete Syphilis test published in a peer-reviewed journal and steady progress toward Canadian approval of its TP/HIV self-test. Financially, revenue fell to $24,503 amid order delays linked to a U.S. government shutdown, while operating expenses were reduced, liabilities rose, working capital deficit widened slightly and debt restructuring talks continued, underscoring ongoing going-concern pressures.
The most recent analyst rating on (TSE:MIR) stock is a Sell with a C$0.06 price target. To see the full list of analyst forecasts on Medmira stock, see the TSE:MIR Stock Forecast page.
Spark’s Take on MIR Stock
According to Spark, TipRanks’ AI Analyst, MIR is a Neutral.
The score is primarily weighed down by weak financial performance (ongoing losses, cash burn, negative equity, and high leverage). Technical indicators add mild downside bias (negative MACD and price below the 200-day average), while valuation is constrained by loss-making status and no dividend support.
To see Spark’s full report on MIR stock, click here.
More about Medmira
MedMira Inc. is a Halifax-based medical diagnostics company that develops and owns Rapid Vertical Flow (RVF) technology for rapid testing. Its Reveal, Multiplo and Miriad branded assays provide instant diagnosis for infectious diseases such as HIV and hepatitis C, serving hospitals, laboratories, clinics and individual consumers in global markets.
Average Trading Volume: 48,102
Technical Sentiment Signal: Sell
Current Market Cap: C$45.61M
Learn more about MIR stock on TipRanks’ Stock Analysis page.